biotechnology
60 stories related to this topic, newest first.
benzinga.comEli Lilly Adds Amylin Receptor Agonists to Camurus Collaboration Agreement
Camurus announced on June 1, 2026 that Eli Lilly exercised its option to include amylin receptor agonists in their June 2025 collaboration and license agreement. The move triggers a $5 million payment and extends Lilly's rights to Camurus' FluidCrystal technology.
newscientist.com3D-Printed Lymph Node Models Improve CAR T-Cell Reprogramming to 75% in Lab Tests
Researchers in Barcelona used 3D-printed gels that mimic lymph node texture to produce CAR T-cells faster and at higher efficiency than standard plastic-dish methods. The approach cut production time and raised the share of successfully engineered cells from 50 to 75 percent.
The Japan TimesAustralian Lab-Grown Brain Cells Play Doom on Silicon Chip
Researchers at Cortical Labs trained roughly 200,000 living human neurons to control the 1990s video game Doom. The cells, grown from donated blood stem cells, sit on a silicon chip that converts their electrical signals into game inputs.
techjuice.pkAustralian Scientists Grow Neurons on Silicon Chip to Play Classic Video Game Doom
@AFP reported that Australian researchers trained lab-grown brain cells on a silicon computer chip to play the 1990s video game Doom.
The GuardianGalleri Blood Test Shows No Significant Reduction in Advanced Cancers but Cuts Stage 4 Diagnoses by 14% in Large NHS Trial
A multi-cancer early detection blood test did not reduce late-stage diagnoses when added to standard screening. Data were presented at the American Society of Clinical Oncology meeting in Chicago.
koreaherald.comAptose Biosciences Delays Closing of Hanmi Acquisition to June
Aptose Biosciences said regulatory approvals in South Korea are still pending for its planned acquisition by Hanmi Pharmaceutical. The companies now target closing in June and have received an additional loan advance to continue operations.
ForbesBiomanufacturing Shift Focuses on Real-Time Sensing and AI Integration
New in-line sensors and continuous AI models allow operators to track metabolites inside bioreactors instead of relying on delayed offline samples. Industry data show batch failure rates of 5% to 10% for biologics, with individual losses reaching tens of millions of dollars. The…
Australia to Introduce Capital Gains Tax Legislation Thursday
Labor will introduce legislation on Thursday that replaces the 50 percent CGT discount with an inflation-linked reduction. The government is still consulting on possible carve-outs for startups and biotechnology firms. Industry leaders say the unresolved details have already affe…
StatLongevity conference in Berkeley draws founders and researchers for health testing
The Vitalist Bay event held May 14 in Berkeley featured blood testing, workshops, and talks on aging. Organizers described the gathering as a shift from movement to industry.
BenzingaAnalysts Initiate Coverage on Three Biotech and Aerospace Stocks
Mizuho, Roth Capital, and an unnamed GE Aerospace analyst started coverage on Century Therapeutics, BioAge Labs, and GE Aerospace with positive ratings and price targets.
BloombergKardigan Files for U.S. IPO to Fund Three Late-Stage Cardiovascular Drugs
Kardigan submitted paperwork for a U.S. initial public offering. The filing states the proceeds will support three late-stage drug candidates aimed at the underlying mechanisms of cardiovascular disease.
FortuneFormer Palantir Executives Launch Perceptic With $12 Million Seed Round
Three ex-Palantir executives unveiled an end-to-end AI platform for drug development and secured $12 million in seed funding led by Accel. The startup says its software is already in paid use at multiple large pharmaceutical companies.
BenzingaAkari Therapeutics Stock Falls After 255 Percent Weekly Gain
Akari Therapeutics PLC shares declined on Tuesday following a 255 percent surge late last week. The movement came after the company reported preclinical results for its AKTX-101 asset in KRAS-mutated pancreatic cancer models.
StatBigHat Biosciences CEO Describes Limits of AI in Antibody Drug Design
Peyton Greenside, CEO of BigHat Biosciences, said AI can generate antibody designs quickly but that downstream testing still requires substantial time and expense. The company, founded in 2019, has completed projects with several large pharmaceutical partners.
Los Angeles TimesBiotech Firm Hatches Chicks in Artificial Eggshell System
Colossal Biosciences reported hatching 26 chickens from a 3D-printed lattice that mimics an eggshell. Independent researchers said the structure functions as an artificial eggshell but lacks other egg components.
thehindu.comMerck drug combination reduces lung cancer progression risk in trial
A Merck antibody-drug conjugate combined with Keytruda lowered the risk of tumor progression by 65 percent in a Phase 3 lung cancer study. The results come from an abstract released ahead of the American Society of Clinical Oncology meeting.
StatBiogen and Denali Parkinson’s Drug Fails Randomized Trial
Biogen and Denali Therapeutics reported that an experimental therapy targeting the LRRK2 protein did not slow Parkinson’s disease progression in a randomized study of 648 adults. The companies announced the results on May 21, 2026.
SemaforColossal Biosciences Develops Device to Hatch Chicks in Synthetic Eggs
Colossal Biosciences said Tuesday it created a synthetic egg device that hatched two dozen chicks. The company transferred fertilized eggs to a lab incubator and later returned the hatched chicks to its farm.
cointelegraph.com23andMe Reemerges as Nonprofit After Founder Purchase
Anne Wojcicki bought the genetic testing company after it faced near-loss. The firm now operates as a nonprofit. A STAT interview discusses changes and continuity.
thehindu.comCompany Hatches Chick from 3D-Printed Egg in Giant Moa Project
Colossal Biosciences announced the hatching of baby chickens from a 3D-printed lattice structure designed to replicate the eggshell of the extinct giant moa. The Texas-based company said the development is a milestone for its de-extinction efforts.
manilatimes.netDyadic Applied BioSolutions to Present at Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions announced it will participate in the Sidoti Virtual Investor Conference scheduled for May 20-21, 2026. President and Chief Operating Officer Joe Hazelton is set to present on May 20 at 10:00 a.m. ET.
techjuice.pkResearchers Develop Implantable Materials With Engineered Bacteria for Drug Delivery
Scientists created implantable living materials that use contained engineered bacteria to release therapeutics on their own. The approach addresses a key challenge in using microbes for medical treatments.
The IndependentBiotech Company Hatches Chicks in Artificial Eggshell
A company working on de-extinction hatched 26 live chicks using a 3D-printed lattice that mimics an eggshell. Independent scientists called the technology impressive but said it is not a complete artificial egg and that reviving extinct species remains unlikely.
The TimesBiotech Firm Develops Artificial Egg for Giant Moa Revival
Colossal Biosciences has created a shell-less artificial egg that successfully hatched chicken chicks. The Texas company aims to use scaled-up versions to revive the extinct giant moa and dodo.
Usa TodayColossal Biosciences Develops Artificial Egg for Chicken Hatching
Colossal Biosciences announced Tuesday that it has successfully hatched more than 30 chickens using a 3D-printed artificial egg developed over two years. The device is intended to support the company's efforts to revive the extinct South Island Giant Moa.
Fox NewsTexas Company Hatches Chicks From Artificial Eggs in First Test
A Texas company has hatched 26 healthy chickens using reusable titanium artificial eggs lined with a bioengineered membrane. The technology is intended to support future efforts to revive extinct birds such as the dodo and moa.
The Sydney Morning HeraldAmplia Therapeutics Starts Phase 2b Trial of Narmafotinib for Pancreatic Cancer
Amplia Therapeutics has begun a Phase 2b study testing daily dosing of narmafotinib in newly diagnosed pancreatic cancer patients. The trial combines the drug with standard chemotherapy and will initially enroll 12 patients across Australian sites.
prnewswire.comAnaveon Appoints Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Anaveon announced two executive appointments on May 19, 2026. Eric Zanelli will serve as Chief Scientific Officer and Jill Jene will serve as Chief Business Officer.
ncbi.nlm.nih.govKrystal Biotech Develops Gene Therapy for Rare Skin Disorder
Suma Krishnan, founder and president of Krystal Biotech, discussed a gene therapy treatment for epidermolysis bullosa at an America 250 event. The therapy targets the rare disease that leaves children born without fully formed skin.
forbes.comU.S. Biotech Firms Spent $60 Billion on Chinese Drugs in First Quarter
American drug companies purchased Chinese-developed molecules at a pace that would double last year's total. The purchases have created divisions within the industry over whether to treat Chinese firms as partners or competitors.
benzinga.comQuince Therapeutics Acquires Orphai Therapeutics and Raises Up to $187 Million
Quince Therapeutics announced the acquisition of Orphai Therapeutics and a concurrent private placement to fund development of an inhaled rapamycin formulation for pulmonary diseases. The deal brings LAM-001 into Quince's pipeline and extends the company's cash runway through 202…
benzinga.comSilexion Therapeutics Reports First Quarter 2026 Financial Results
Silexion Therapeutics reported financial results for the three months ended March 31, 2026. The company also provided updates on regulatory approvals and planned clinical trials for its lead product candidate.
app.buzzsumo.comSpinach Chloroplasts Implanted in Mice Eyes Produce Light-Driven Molecules and Reduce Inflammation in Preliminary Study
Researchers isolated chloroplasts from spinach bought at a Singapore supermarket and introduced thylakoid grana into mouse eyes. The plant-derived machinery transforms light into energy-carrying molecules and reduces inflammation. The study, published in Cell, draws on evolutiona…
StatFDA Approves BeOne Medicines’ Beqalzi for Relapsed/Refractory Mantle Cell Lymphoma
BeOne Medicines received FDA approval for its BCL-2 inhibitor Beqalzi to treat relapsed or refractory mantle cell lymphoma. The drug is the first BCL-2 inhibitor specifically cleared for this indication in the U.S. Separately, CREATE Medicines raised $122 million to advance its i…
StatBiogen Advances Tau-Targeting Alzheimer’s Drug to Phase 3 Despite Mixed Phase 2 Data
Biogen reported that its drug diranersen reduced tau levels in spinal fluid and brains of patients with early-stage Alzheimer’s in a Phase 2 trial. The reductions correlated with slower cognitive decline, though the study did not meet its primary efficacy goal of showing a dose r…
rte.ieCREATE Medicines Raises $122 Million to Advance CAR-T Candidates Into Human Trials
The biotechnology company, formerly known as Myeloid Therapeutics, secured the funding from Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. CREATE Medicines, cofounded by Siddhartha Mukherjee, is developing CAR-T therapies using myeloid cells to target soli…
StatRegenxbio Gene Therapy for Duchenne Muscular Dystrophy Succeeds in Trial
Regenxbio announced on May 14, 2026 that its experimental treatment produced high levels of a miniaturized muscle protein, clearing the path for an FDA submission. The Rockville, Md.-based company aims to offer a safer and more effective option than Sarepta Therapeutics’ Elevidys…
etftrends.comDyadic International Reports 182% Revenue Increase in Q1 2026
Dyadic International reported first-quarter 2026 revenue of $1.1 million, up 182% from the same period in 2025. The company said the growth was driven by higher research and development revenue, grant revenues and milestone payments. Dyadic is transitioning from a platform techno…
StatScientists Link Boy’s Brain Tumor to Gene Therapy Viruses
A 13-month-old boy with a rare disease received an experimental gene therapy after his stem cell transplant failed. A routine scan later revealed a golf-ball-sized tumor on his brain. Scientists have linked the tumor to viruses used in the gene therapy, according to a STAT report…
prnewswire.comGinkgo Bioworks to Close Traditional Labs and Spin Off Biosecurity Unit
The Boston company reported cumulative net losses of $6 billion since 2020 and a 24 percent revenue decline last year. It will focus on selling AI-driven lab robots to drug companies and universities while offering cloud access to automated experiments. The company already operat…
fortune.comIsomorphic Labs Raises $2.1 Billion While Anduril Closes $5 Billion Funding Round
Isomorphic Labs, founded by Demis Hassabis, announced a $2.1 billion Series B funding round. Anduril simultaneously closed a $5 billion Series H at a $61 billion valuation. Thrive Capital led both rounds, with Andreessen Horowitz also participating in Anduril's financing.
app.buzzsumo.comEngineered E. coli Produce 4.2 g/L of Sunscreen Compound Gadusol in Lab Tests
Researchers at Jiangnan University inserted zebrafish genes into bacteria to synthesise gadusol, a naturally occurring UV-protective compound found in fish eggs and coral. The process raised output nearly 93-fold to levels that could support commercial development of an eco-frien…
FortuneIsomorphic Labs Raises $2.1 Billion as Anduril Closes $5 Billion Funding
Isomorphic Labs announced a $2.1 billion Series B funding round while Anduril closed a $5 billion Series H at a $61 billion valuation. Thrive Capital led both rounds with Andreessen Horowitz also leading Anduril's round. The announcements occurred within the last 24 hours as both…
StatScientists Link Boy’s Brain Tumor to Gene Therapy Viruses
Doctors identified a link between a gene therapy treatment and a brain tumor in a young patient with a rare disease. The case is described as rare, with medical professionals stating that treatment risks must be weighed against benefits. The patient had previously undergone a ste…
prnewswire.comEncoded Therapeutics Reports Initial Results from Gene Therapy Trial for Dravet Syndrome
A trial by Encoded Therapeutics involving 21 children with Dravet syndrome showed that sirolimus, used alongside steroids to prevent immune responses, could blunt the therapy's benefits. The findings, published May 13, 2026, come from a Boston-based report examining a key concern…
prnewswire.comMetis TechBio Raises $270 Million in Hong Kong IPO
Metis TechBio, a biotechnology company using artificial intelligence to deliver and formulate drugs, completed a $270 million initial public offering. The company is set to begin trading in Hong Kong. @business reported the development.
manilatimes.netBristol Myers Squibb Partners With Hengrui Pharma on Early-Stage Programs
Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs. The agreement is the latest instance of a global pharmaceutical company seeking medicines from China. Separately, Viiv lost an HIV treatment patent case while other c…
kr-asia.comBristol Myers Squibb Partners With China’s Hengrui Pharma on More Than a Dozen Early-Stage Programs
Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs on May 12, 2026. Hims & Hers reported first-quarter sales of $608 million, below analyst estimates, and posted a net loss of $92 million. Other biotech developments in…
prnewswire.comCapsida Biotherapeutics Updates Investigation Into Death of Child in CAP-002 Gene Therapy Trial
The company said Tuesday it remains unable to determine what caused the death of a child last September in a trial of its experimental brain-targeted therapy CAP-002. Scientists have been blocked from full investigation because the hospital has declined to provide autopsy tissue…
benzinga.comMiNK Therapeutics Reports agenT-797 Produces Context-Dependent Immune Responses in Cancer and ARDS
MiNK Therapeutics presented clinical data at the ASGCT 2026 meeting showing its off-the-shelf iNKT cell therapy agenT-797 drove different immune responses in patients with solid tumors and those with acute respiratory distress syndrome. The same product batch from one donor activ…
The IndependentChinese Scientists Develop Self-Degrading Plastic Material
Researchers incorporated two strains of Bacillus subtilis bacteria into polycaprolactone to create a material that breaks down completely in six days when activated. The bacteria produce complementary enzymes that degrade the polymer into its base building blocks without forming…
/writing-hand-finger-close-up-stop-domino-746367-pxhere.com1-42bcc7ed1d4a4e4a8d611e2a55852b79.jpg)
investopedia.comArvinas Enters Material Definitive Agreement
Arvinas Inc. disclosed entry into a material definitive agreement on May 12 2026. The pact alters the company's contractual obligations and sets contractual milestones that require subsequent regulatory filings.
South China Morning PostChina Ranks Third in Global AI Competitiveness Index for Life Sciences
China placed third in the latest Global AI Competitiveness Index for biotechnology, healthcare and longevity with a score of 85.3. The index was released on May 11, 2026 by Deep Knowledge Group. Hong Kong ranked third among city-level innovation hubs.
thesouthafrican.comColossal Biosciences Says Its Genetically Modified Dire Wolf Project Animals Have Reached Breeding Age
The Texas-based company's three dire wolves, the world's first de-extinct animals, are now breeding-aged as of 2026. Romulus, Remus and Khaleesi, born in late 2024 and early 2025, live in a 2,000-acre preserve where they have learned to process whole deer carcasses.
prnewswire.comCapricor Therapeutics Sues Nippon Shinyaku and NS Pharma Over Pricing Dispute on Duchenne Muscular Dystrophy Therapy Deramiocel
Capricor Therapeutics filed suit in New Jersey state court on May 8, 2026, accusing Nippon Shinyaku and its U.S. subsidiary NS Pharma of failing to execute marketing plans for deramiocel and refusing to correct a pricing formula flaw discovered in March 2025.
link.springer.comStudy Characterizes Polysaccharide–Protein Composite Gels for Potential Dysphagia Applications
A study published on 08 May 2026 details the creation of composite gels using high-acyl gellan gum and hydroxypropyl methylcellulose. Scientists screened 12 candidate polysaccharides permitted under GB 2760-2014, identifying only two that met all criteria for dysphagia-oriented a…
uctoday.comModerna's mRESVIA Faces Challenges in RSV Vaccine Market
A Seeking Alpha analysis reported that Moderna's mRESVIA RSV vaccine has struggled to gain market share against established competitors in 2026. Pfizer and GSK secured early advantages through supply chain and contract arrangements following their first-to-market launches.
forbes.comImmunai Expands Oncology Collaboration With AstraZeneca
The New York-headquartered, Israeli-founded AI biotech company Immunai has expanded its multi-year collaboration with AstraZeneca in oncology clinical development. Under the agreement, Immunai is eligible to receive up to $37.5 million over 2026 and 2027. The companies will conti…
insidermonkey.comImmunityBio Reports Record Q1 Revenue Tripling Year-Over-Year Driven by Anktiva
Zoetis reported lower-than-expected first-quarter 2026 results driven by U.S. headwinds and lowered its financial guidance. Separately, ImmunityBio shares dropped 11.46 percent despite record revenue growth from its cancer drug Anktiva.
prnewswire.comEntrada Duchenne Therapy Falls Short in Early Trial
Entrada Therapeutics reported that its next-generation exon-skipping drug for Duchenne muscular dystrophy did not meet expectations in an early-stage study. The company is among several developing improved treatments aimed at increasing functional dystrophin production in patient…